Tags

Type your tag names separated by a space and hit enter

[Long term experience with Stalevo in Szeged, Hungary].
Ideggyogy Sz. 2009 May 30; 62(5-6):178-80.IS

Abstract

The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in patients with Parkinson's disease. In this study we summarized the clinical data of our patients treated with Stalevo for the longest period. We can concluded, that after switching to Stalevo due to wearing off, the average levodopa doses were lower then before and the motor complications were milder. After 3 years of Stalevo therapy the levodopa doses were increased but still did not reach the average doses before introducing Stalevo. After switching the patients' general well-being was improved as indicated by the visual analogue scale. In summary, the Stalevo treatment is safe and effective for long run and improves the patients' quality of life.

Authors+Show Affiliations

Szegedi Tudományegyetem, Neurológiai Klinika, Szeged. klivenyi@nepsy.szote.u-szeged.huNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

hun

PubMed ID

19579666

Citation

Klivényi, Péter, and László Vécsei. "[Long Term Experience With Stalevo in Szeged, Hungary]." Ideggyogyaszati Szemle, vol. 62, no. 5-6, 2009, pp. 178-80.
Klivényi P, Vécsei L. [Long term experience with Stalevo in Szeged, Hungary]. Ideggyogy Sz. 2009;62(5-6):178-80.
Klivényi, P., & Vécsei, L. (2009). [Long term experience with Stalevo in Szeged, Hungary]. Ideggyogyaszati Szemle, 62(5-6), 178-80.
Klivényi P, Vécsei L. [Long Term Experience With Stalevo in Szeged, Hungary]. Ideggyogy Sz. 2009 May 30;62(5-6):178-80. PubMed PMID: 19579666.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Long term experience with Stalevo in Szeged, Hungary]. AU - Klivényi,Péter, AU - Vécsei,László, PY - 2009/7/8/entrez PY - 2009/7/8/pubmed PY - 2009/7/25/medline SP - 178 EP - 80 JF - Ideggyogyaszati szemle JO - Ideggyogy Sz VL - 62 IS - 5-6 N2 - The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in patients with Parkinson's disease. In this study we summarized the clinical data of our patients treated with Stalevo for the longest period. We can concluded, that after switching to Stalevo due to wearing off, the average levodopa doses were lower then before and the motor complications were milder. After 3 years of Stalevo therapy the levodopa doses were increased but still did not reach the average doses before introducing Stalevo. After switching the patients' general well-being was improved as indicated by the visual analogue scale. In summary, the Stalevo treatment is safe and effective for long run and improves the patients' quality of life. SN - 0019-1442 UR - https://www.unboundmedicine.com/medline/citation/19579666/[Long_term_experience_with_Stalevo_in_Szeged_Hungary]_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -